



Management of CIN and HPV Eradication Strategies for the Prevention of Uterine Cervical Cancer

Guest Editor:

Dr. Masaru Sakamoto

1. Department of Gynecology, Sasaki Foundation Kyoundo Hospital, Tokyo, Japan
2. Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan

Deadline for manuscript submissions:

closed (31 January 2022)

Message from the Guest Editor

Dear Colleagues,

In this Special Issue, the main aim is to help to prevent uterine cervical cancer. For the prevention of uterine cervical cancer, there are two categories, i.e., primary and secondary prevention. As primary prevention of uterine cervical cancer, HPV vaccines are used for the prevention of HPV infection worldwide. As secondary prevention of uterine cervical cancer, diagnosis and management of CIN is performed.

We are interested in a broad area of research, focusing primarily on the management of CIN and HPV eradication strategies for the prevention of uterine cervical cancer. In addition, we are calling for manuscripts dealing with vaccine trials (preclinical and clinical) and strategies to develop a more effective HPV vaccine. We aim to present a combination of manuscripts dealing with different vital aspects of HPV, which can be exploited to develop more effective eradication strategies for HPV infection.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com